Get the Stockscreener App
274.04
2.13%
5.72
Pre-market:
272.21
-1.83
-0.67%
Insulet Corporation stock is traded at $274.04, with a volume of 689.25K.
It is up +2.13% in the last 24 hours and down -3.33% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$268.32
Open:
$272.38
24h Volume:
689.25K
Relative Volume:
1.05
Market Cap:
$19.24B
Revenue:
$1.98B
Net Income/Loss:
$420.90M
P/E Ratio:
46.92
EPS:
5.84
Net Cash Flow:
$218.20M
1W Performance:
+4.74%
1M Performance:
-3.33%
6M Performance:
+14.66%
1Y Performance:
+66.78%
1-Day Range:
$270.42
$274.85
1-Week Range:
$255.64
$274.85
52-Week Range:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
274.04 | 19.24B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
127.21 | 220.62B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.67 | 151.86B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
374.27 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.13 | 115.57B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.35 | 41.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Insulet Gains 62.9% in a Year: What's Driving the Stock? - Yahoo Finance Australia
Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5% - Yahoo Finance
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Insulet Corp issues $450 million in senior notes By Investing.com - Investing.com Canada
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Com - GuruFocus.com
PODD Stock Gains Following the Launch of Omnipod 5 in Australia - Yahoo Finance
Insulet Corp issues $450 million in senior notes - Investing.com India
Insulet Closes $450 Million Senior Notes Issuance - TipRanks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers - Yahoo Finance
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 - Yahoo Finance
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day - TradingView
Insulet announces pricing of senior notes due 2033 - MSN
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - BioSpace
Insulet's RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition - Nasdaq
Omnipod 5 improves diabetes control in clinical trial By Investing.com - Investing.com South Africa
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - Lelezard
Insulet says data shows significant glycemic improvement with Omnipod 5 - Seeking Alpha
Insulet Reports Glycemic Improvements With Omnipod Automated Insulin Delivery System - Marketscreener.com
Insulet’s RADIANT trial demonstrates ‘meaningful’ glycemic improvements - TipRanks
Omnipod 5 improves diabetes control in clinical trial - Investing.com
Breakthrough: Omnipod 5 Automated System Adds 5.4 Hours of Stable Blood Sugar Daily - StockTitan
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan - TradingView
Insulet prices $450 million in senior notes due 2033 By Investing.com - Investing.com South Africa
Insulet announces proposed financing transactions - MSN
Insulet plans $450 million senior notes offering By Investing.com - Investing.com Australia
Insulet’s corporate family rating upgraded by Moody’s Ratings - Investing.com Canada
Insulet Announces Pricing of $450 Million Senior Notes - TipRanks
Insulet prices $450 million in senior notes due 2033 - Investing.com India
Insulet Announces Pricing of Senior Notes Due 2033 - Business Wire
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing - StockTitan
Insulet Announces Proposed Financing Transactions - citybiz
Insulet Corporation (PODD): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Insulet Corp. gets credit rating upgrade by S&P on strong performance and expected deleveraging - Investing.com South Africa
Insulet expands Omnipod 5 to more countries, prices $450M offering - Mass Device
Insulet Chief Technology Officer Mark Field leaves - Yahoo Finance
Insulet Expands Omnipod® 5 to Four More International Markets - 01Net
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes - 01Net
Insulet Announces $450 Mln Offering Of Senior Unsecured Notes Due 2033 - Nasdaq
Insulet plans $450 million senior notes offering - Investing.com India
Insulet Announces $450M Senior Notes Offering - TipRanks
Insulet Plans $450 Million Senior Notes Offering -March 18, 2025 at 08:07 am EDT - Marketscreener.com
Insulet Secures Major Financial Overhaul: $450M Notes Plus Enhanced $500M Credit Line - StockTitan
Insulet Launches Omnipod 5 Insulin Delivery System in Australia -March 18, 2025 at 07:01 am EDT - Marketscreener.com
Insulet's Game-Changing Automated Insulin System Expands Global Reach to Australia, Belgium, Canada - StockTitan
Revolutionary Diabetes Treatment Trial: Insulet's Omnipod 5 Could End Daily Insulin Injections - StockTitan
Insulet Stock Leans Bullish (Technical Analysis) (NASDAQ:PODD) - Seeking Alpha
Insulet Corporation (PODD) Announces Leadership Change in Techno - GuruFocus.com
Insulet CTO Mark Field Departs for New Opportunities - TipRanks
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):